Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To establish the superiority of dabrafenib and trametinib combination therapy over dabrafenib and trametinib placebo (dabrafenib monotherapy) with respect to progression-free survival (PFS) for subjects with advanced/metastatic BRAF V600E/K mutation-positive cutaneous melanoma.
Critère d'inclusion
- Cutaneous melanoma - aggressive form of skin cancers